Onglyza FDA Safety Announcement
The U.S. Food and Drug Administration (FDA) issued a safety announcement stating that it wanted to investigate a study published in the New England Journal of Medicine which reported an increased rate of hospitalization for heart failure in patients using Onglyza. After completing their investigation, a majority of an FDA advisory committee recommended that Onglyza’s label be updated to include the increased risk of heart failure. One member of the committee voted to remove the drug from the market altogether. AstraZeneca, the manufacturer of Onglyza, had no given no prior warnings to patients or prescribing physicians concerning the increased risk of heart failure.
Onglyza Side Effects
Onglyza (saxagliptin) is a drug used in conjunction with diet and exercise to help control high blood sugar in people with Type 2 diabetes who do not have diabetic ketoacidosis. It was approved by the FDA for use to treat Type 2 diabetes in adults in 2009. Onglyza works by helping the pancreas secrete more insulin and stop the liver from making excess sugar. If you or a loved one has taken Onglyza and experienced any of the following, please call our firm:
- Heart failure
- Death caused by heart failure
- Fatal heart attack
AFFECTED BY ONGLYZA?
You May Be Entitled to Compensation. Call Now!
Are You Eligible for an Onglyza Lawsuit?
The Feeney Law Firm is committed to seeking justice for those affected by Onglyza. Fighting to keep people safe from corporate greed and self-interest is our passion. We are here to help make that process as simple as possible for you and your family. Call us now at 1-800-809-0911 for a FREE consultation. Don’t wait; your time to file an Onglyza lawsuit may be limited.
Do not stop taking these drugs without first speaking to your doctor.